Results 101 to 110 of about 31,041 (297)

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed   +12 more
wiley   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo   +10 more
wiley   +1 more source

Study Factors Associated with Early Complications of the Permanent Pacemaker Implantation: A Research Report in Vietnam

open access: yesJournal of Pharmacy and Bioallied Sciences
Introduction: The permanent pacemaker implantation has a history of more than 60 years with improved mortality and quality of life but also recorded many complications.
Giang Song Tran   +2 more
doaj   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

open access: yesESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz   +5 more
wiley   +1 more source

Red blood cell endothelial nitric oxide synthase: A major player in regulating cardiovascular health

open access: yesBritish Journal of Pharmacology, EarlyView., 2023
Abstract Red blood cells (RBCs) have traditionally been seen as simple carriers of gases and nutrients in the body. One important non‐canonical function of RBCs in the cardiovascular system is the regulation of nitric oxide (NO) metabolism. It has been shown that RBCs can scavenge NO, transport NO metabolites and produce NO in hypoxic conditions ...
Anthea LoBue   +7 more
wiley   +1 more source

Editorial: Advances in imaging and treatment of embolic stroke of undetermined source

open access: yesFrontiers in Neurology, 2022
Bing Tian, Xia Tian, Chengcheng Zhu
doaj   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

open access: yesESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge   +19 more
wiley   +1 more source

Review of Antiplatelet Therapy for the Management of Acute Coronary Syndromes

open access: yesJournal of Medical Sciences and Health, 2016
Dear editor, Currently, cardiovascular diseases are the most common cause of morbidity and mortality in worldwide. Acute coronary syndromes (ACS) form a significant percentage of this disease spectrum.
Ganesh Nallur Shivu
doaj  

Home - About - Disclaimer - Privacy